Industries Market Research Reports

This Frost Radar benchmarks companies offering lab automation and monitoring solutions for diagnostics labs: hospital and independent labs including multi-chain organized, unorganized, and university labs. Lab automation solutions cover aspects of operations such as pre-pre-analytical, pre-analytical, and post-analytical workflows, whereas lab...

This Frost Radar benchmarks companies and their solutions that enable the exchange and use of data between healthcare applications. Interoperability improves continuity of care, increases communication and connectivity between different stakeholders (e.g., payors, providers, patients, public health bodies), and reduces inefficiencies. Organizat...

This Frost Radar for the laboratory information management systems (LIMS) industry benchmarks providers offering workflow management and paperless tracking capabilities to help improve process efficiencies for life sciences companies. LIMS have several functionalities, such as obtaining, storing, managing, retrieving, and recording laboratory data...

In the cloud industry and most other technology-related industries, 2024 will be all about artificial intelligence (AI). Businesses are grappling with how they can leverage AI (particularly generative AI) to meet their goals. Public cloud providers are at the forefront of efforts to accelerate customers AI adoption by developing foundational model...

As cell and gene therapy (CGT) moves from ultra-rare indications to more common indications, manufacturing capabilities will have to expand to support the commercial requirements of these diseases. Contract research organizations (CROs) can play a critical role in long-term genetic analysis and monitor safety and efficacy up to 15 years after treat...

23 Aug 2022  |  North America  |  Frost Radar

Frost Radar™: US Liquid Biopsy, 2022

A Benchmarking System to Spark Companies to Action - Innovation that Fuels New Deal Flow and Growth Pipelines

Infographics

×

The oncology space is maturing rapidly. With the arrival of blood-based assays for cancer screening and the emphasis on early detection, the liquid biopsy segment is seeing increased consolidation and high-impact acquisitions, such as Illumina and GRAIL, Exact Sciences and Thrive Earlier Detection, and Roche Foundation Medicine and Lexent Bio. Comp...